VDCR as a treatment option for refractory or relapsed multiple myeloma in Bortezomib pretreated patients, a single center experience

被引：0
|
作者：
Dobrosch, L. [1 ]
Hahn-Ast, C. [1 ]
Mayer, K. [1 ]
von Lilienfeld-Toal, M. [1 ]
Brossart, P. [1 ]
Janzen, V [1 ]
机构：
[1] Univ Klinikum Bonn, Med Klin 3, Bonn, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P543
引用
收藏
页码：162 / 162
页数：1
相关论文
共 50 条
  • [31] Second autologous stem cell transplantation as treatment option for relapsed patients with multiple myeloma: A single center experience (CIC 859)
    Ganeva, P.
    Petrov, Y.
    Mincheff, M.
    Tonev, I.
    Guenova, M.
    Gartcheva, L.
    Michova, A.
    Arnaudov, G.
    Mihaylov, G.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S471 - S471
  • [32] Coagulation-related effect of bortezomib treatment in patients with relapsed or refractory multiple myeloma
    Zangari, Maurizio
    Guerrero, Jose
    Cavallo, Federica
    Burns, Michael J.
    Prasad, Keshava
    Adcock, Dot
    Marlar, Richard
    Tricot, Guido
    Fink, Louis
    BLOOD, 2007, 110 (11) : 803A - 803A
  • [33] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    BLOOD, 2022, 140 : 7246 - 7248
  • [34] A SINGLE CENTER EXPERIENCE OF POMALIDOMIDE PLUS DEXAMETHASONE (PD) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
    Duran, M.
    Tombuloglu, M.
    Tobu, M.
    Vural, F.
    Sahin, F.
    Patir, P.
    Uysal, A.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S18 - S19
  • [35] IMPACT OF BORTEZOMIB IN THE SURVIVAL OF PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA WITH RENAL FAILURE. EXPERIENCE OF A SINGLE CENTRE.
    Hernandez, B.
    Calle, C.
    Carreno, A.
    Rodriguez, M.
    Nebro, M.
    Tallon, I.
    Vanegas, R.
    HAEMATOLOGICA, 2012, 97 : 614 - 614
  • [36] Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
    Reece, Donna E.
    Trieu, Young
    Masih-Khan, Esther
    Atenafu, Eshetu G.
    Chen, Christine
    Prica, Anca
    Tiedemann, Rodger
    Trudel, Suzanne
    Kukreti, Vishal
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (07): : 387 - 394
  • [37] Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study
    Bernard Regidor
    Marissa-Skye Goldwater
    Jessica Wang
    Sean Bujarski
    Regina Swift
    Benjamin Eades
    Marsiye Emamy-Sadr
    Shahrooz Eshagian
    Gary Schwartz
    Tanya M. Spektor
    James R. Berenson
    Annals of Hematology, 2021, 100 : 2061 - 2070
  • [38] Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Retrospective Single Center Experience
    Garderet, Laurent
    Polge, Emmanuelle
    Gueye, Mor Seny
    Kellil, Chaima
    Ova, Jeanny Guelongo Okouango
    Beohou, Eric
    Labopin, Myriam
    Mohty, Mohamad
    BLOOD, 2015, 126 (23)
  • [39] POMALIDOMIDE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): EXPERIENCE CENTER
    Cuesta Garcia, A.
    HAEMATOLOGICA, 2015, 100 : 104 - 104
  • [40] Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Kukreti, Vishal
    BLOOD, 2011, 118 (21) : 1266 - 1267
12345